2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 029

Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis
Abstract Number: 085

Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?
Abstract Number: 118

Pain Experience and Treatment in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Lupus Erythematosus Registry
Abstract Number: 133

Pathologic Lymphangiogenesis in Mouse Model and Patients with Pulmonary Arterial Hypertension
Abstract Number: 124

Patient perspectives, barriers, and next steps in a health care transition clinic for pediatric to adult rheumatology
Abstract Number: 041

Pediatric Behçet’s Disease: A 13-Year Single-Center Experience Highlighting Diagnostic Delays and High Neurological Burden
Abstract Number: 111

Pediatric chronic nonbacterial osteomyelitis outcomes after NSAID or TNF inhibitor discontinuation, a registry cohort with two year follow up data
Abstract Number: 057

Pediatric Learners’ Knowledge Retention and Diagnostic Confidence after High-Fidelity Pediatric Rheumatology Simulation
Abstract Number: 034

Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Management Across Countries: A Survey to Inform Future Comparative Effectiveness Research
Abstract Number: 116

Pilot of Adalimumab Withdrawal (PAW): Preliminary Analysis of Feasibility and Acceptability of Self-Collected Capillary Blood Samples
Abstract Number: 102

Positive Affect and Emotion Regulation Protect Juvenile-Onset Lupus and Dermatomyositis Patients from Emotional Distress: Longitudinal Analysis of Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study Parent-Reported Resiliency Data
Abstract Number: 137

Preliminary Findings: Single Nuclei RNAseq of Juvenile Dermatomyositis Muscle Biopsies Suggests Unique Myositis Specific Autoantibody Cell Population
Abstract Number: 012

Prevalence and Impact of Adverse Childhood Experiences in Pediatric Systemic Lupus Erythematosus
Abstract Number: 091

Psychosocial Burden in Juvenile Systemic Sclerosis: Insights from PedQL Outcomes
Abstract Number: 064

Recognizing Paradoxical Psoriasis in TNF-Inhibitor–Treated Pediatric Rheumatic Disease: A Saskatchewan Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].